Johnny O supports more aggressive price negotiations, capping out-of-pocket costs and improving price transparency so patients face fewer surprise bills.
Support more aggressive prescription drug price negotiations, caps on out-of-pocket costs, and improved price transparency.
Occurrences
"expand access to prescription price caps."
Evidence
H.R.6166 was introduced in the House on 11/20/2025. Its official title states it would expand the drug price negotiation program under title XI of the Social Security Act, apply prescription drug inflation rebates under Medicare to drugs furnished in the commercial market, and establish out-of-pocket limits on expenditures for prescription drugs under private health insurance. The bill status remains Introduced.
Assessments
The relevant federal measure, H.R.6166, aligns closely with the promise because it would expand Medicare drug price negotiation, extend inflation rebates to the commercial market, and establish private-insurance out-of-pocket limits. Olszewski appears as a cosponsor during his current House term, so this is a serious legislative effort. However, the bill remains only introduced/referred in committee and has not become law or otherwise delivered the promised policy outcome. Under the instruction for serious attempts that fail to deliver, this is never with an effort badge, not partial delivery.